Advanced Cell Technology, 1 Innovation Dr, Ste 3, Worcester, MA 01605, US

Microbiotix is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company has four novel compound series in research and development. Microbiotix developed MBX 500, the first antibiotic that targets the deoxyribonucleic acid polymerase of gram-positive bacteria, including drug resistant strains. The company has an active research program to discover a broad-spectrum antibiotic that targets DNA replication of drug-resistant gram-positive and gram-negative bacteria. In addition to MBX 500, Microbiotix's most advanced antiviral compounds are for the treatment of respiratory syncytial virus (MBX 300) and cytomegalovirus (MBX400) which are in pre-clinical development. It also has an active biodefense program, focused on novel therapeutics for Bacillus Anthraocis and Burkholderia pseudomalli. Based in Worcester, Mass., Microbiotix is involved in the discovery of inhibitors of bacterial biofilm formation and antibiotic resistance.

Alexandria Real Estate Research Park

Gaia Biotech

Agilux Laboratories

Pure Produce